

We claim:

1. A pharmaceutical product or medicament comprising a first component selected from
 - 5,6-dihydroxy-2-{3-[4-(2-isopropoxyphenyl)-piperazin-1-yl]propyl}-hexahydro-isoindole-1,3-dione,
 - 1-{3-[4-(2-isopropoxyphenyl)piperazin-1-yl]propyl}-piperidine-2,6-dione,
 - 2-{3-[4-(2-ethoxyphenyl)piperazin-1-yl]propyl}-3a,4,7,7a-tetrahydro-isoindole-1,3-dione,
 - 1-(3-{4-[2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl}propyl)piperidine-2,6-dione,
 - 5-hydroxy-2-(3-{4-[2-(2,2,2-trifluoroethoxy)phenyl]-piperazin-1-yl}propyl)-hexahydro-isoindole-1,3-dione,
 - 2-{3-[4-(2-Ethoxyphenyl)piperazin-1-yl]propyl}-5-hydroxy-hexahydro-isoindole-1,3-dione,
 - 2-{3-[4-(2-Ethoxyphenyl)piperazin-1-yl]propyl}-5,6-dihydroxy-isoindole-1,3-dione,
 - 4,7-dihydroxy-2-{3-[4-(2-isopropoxyphenyl)-piperazin-1-yl]propyl}-hexahydro-isoindole-1,3-dione,
 - 3-Allyl-1-{3-[4-(2-methoxyphenyl)-piperazin-1-yl]propyl}-4-methyl-pyrrolidine-2,5-dione,
 - 1-(2-Hydroxy-3-{4-[2-(2,2,3,3,3-pentafluoropropoxy)phenyl]-piperazin-1-yl}propyl)-piperidine-2,6-dioneor their pharmaceutically acceptable salts,
 - a second component comprising a muscarinic receptor antagonist,
 - an optional third component comprising testosterone 5 α -reductase inhibitor and a pharmaceutically acceptable carrier.
2. A product or medicament according to claim 1 wherein the product or medicament is a combined preparation.
 3. A product or medicament according to claim 2 wherein the combined preparation is a single dosage form.

1 4. A product or medicament according to claim 2 wherein the combined preparation
2 comprise different dosage forms.

1 5. A product or medicament according to claim 1 wherein the muscarinic receptor
2 antagonist is selected from

3 - (R)-2-[3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-methyl-phenol,

4 - (S)-alpha-cyclohexyl-alpha-hydroxybenzaeneacetic acid-4-(diethylamino)-2-butynyl
5 ester,

6 - (S)-1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]alpha,alpha-diphenyl-3-pyrrolidine
7 acetamide,

8 - (1S)-(3R)-1-azabicyclo[2,2,2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-
9 isoquinolinecarboxylate,

10 - 2-[(1R)-3-(diisopropylamine)-1-phenylpropyl]-4-(hydroxymethyl)phenyl isobutyrate,

11 - 2-Methyl- α,α -diphenyl-iH-imidazole,

12 - (2R)(+)(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-
13 hydroxy-2-cyclopentyl-2-phenylacetamide,

14 - (2R, 2S) (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-
15 2-cyclopentyl-2-phenylacetamide,

16 - (2R) (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
17 cyclopentyl-2-phenylacetamide,

18 - (2S) (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
19 cyclopentyl-2-phenylacetamide

20 or their pharmaceutically acceptable salts.

1 6. A product or medicament according to claim 1 wherein the testosterone 5 α -
2 reductase inhibitor is a type 1 or a type 2 or both a type 1 and type 2 or a dual type 1 and
3 type 2 inhibitor.

1 7. A product or medicament according to claim 6 wherein the testosterone 5 α -
2 reductase inhibitor is a dual type 1 and type 2 inhibitor.

1 8. A product or medicament according to claim 7 wherein the dual type 1 and type 2
2 inhibitor is dutasteride.

1 9. A product or medicament according to claim 6 wherein the testosterone 5 α -
2 reductase inhibitor is a type 2 inhibitor.

1 10. A product or medicament according to claim 9 wherein the type 2 inhibitor is
2 finasteride.

1 11. A method for treatment of a mammal suffering from benign prostatic hyperplasia
2 (BPH), lower urinary tract symptoms (LUTS) associated with or without BPH, comprising
3 administering to said mammal, a therapeutically effective amount of a product or
4 medicament, comprising

5 - 5,6-dihydroxy-2-{3-[4-(2-isopropoxyphenyl)-piperazin-1-yl]propyl}-hexahydro-
6 isoindole-1,3-dione,

7 - 1-{3-[4-(2-isopropoxyphenyl)piperazin-1-yl]propyl}-piperidine-2,6-dione,

8 - 2-{3-[4-(2-ethoxyphenyl)piperazin-1-yl]propyl}-3a,4,7,7a-tetrahydro-isoindole-1,3-
9 dione,

10 - 1-(3-{4-[2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl}propyl)piperidine-2,6-dione,

11 - 5-hydroxy-2-(3-{4-[2-(2,2,2-trifluoroethoxy)phenyl]-piperazin-1-yl}propyl)-
12 hexahydro-isoindole-1,3-dione,

13 - 2-{3-[4-(2-ethoxyphenyl)piperazin-1-yl]propyl}-5-hydroxy-hexahydro-isoindole-1,3-
14 dione,

15 - 2-{3-[4-(2-ethoxyphenyl)piperazin-1-yl]propyl}-5,6-dihydroxy-isoindole-1,3-dione,

16 - 4,7-dihydroxy-2-{3-[4-(2-isopropoxyphenyl)-piperazin-1-yl]propyl}-hexahydro-
17 isoindole-1,3-dione,

18 - 3-allyl-1-{3-[4-(2-methoxyphenyl)-piperazin-1-yl]propyl}-4-methyl-pyrrolidine-2,5-
19 dione,

20 - 1-(2-Hydroxy-3-{4-[2-(2,2,3,3,3-pentafluoropropoxy)phenyl]-piperazin-1-
21 yl}propyl)-piperidine-2,6-dione

22 or their pharmaceutically acceptable salts, a muscarinic receptor antagonist and optionally
23 included testosterone 5 α -reductase inhibitor.

1 12. The method according to claims 11 wherein mammal is animal.

1 13. The method according to claims 11 wherein mammal is human.

- 1 14. The method according to claim 13 wherein human is man.
- 1 15. The method according to claim 13 wherein human is woman.
- 1 16. The method according to claims 11 wherein the said product or medicament is
2 administered as a combined preparation.
- 1 17. The method according to claim 16 wherein the combined preparation is
2 administered as single dosage forms.
- 1 18. The method according to claim 16 wherein the combined preparation is
2 administered in different dosage form.
- 1 19. The method according to claim 18 wherein the different dosage forms are
2 administered simultaneously.
- 1 20. The method according to claim 18 wherein the different dosage forms are
2 administered separately.
- 1 21. The method according to claim 18 wherein the different dosage forms are
2 administered sequentially.
- 1 22. The method according to claims 11 wherein muscarinic receptor antagonist is
2 selected from
- 3 - (R)-2-[3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-methyl-phenol (tolerodine),
4 - (S)-alpha-cyclohexyl-alpha-hydroxybenzaeneacetic acid-4-(diethylamino)-2-butynyl
5 ester (oxybutynin),
6 - (S)-1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]alpha,alpha-diphenyl-3-pyrrolidine
7 acetamide (darifenacin),
8 - (1S)-(3R)-1-azabicyclo[2,2,2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-
9 isoquinolinecarboxylate (solifenacin),
10 - 2-[(1R)-3-(diisopropylamine)-1-phenylpropyl]-4-(hydroxymethyl)phenyl isobutyrate,
11 - 2-Methyl- α,α -diphenyl-iH-imidazole and its pharmaceutically acceptable salts,
12 - (2R)(+)(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-
13 hydroxy-2-cyclopentyl-2-phenylacetamide,
14 - (2R, 2S) (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-
15 2-cyclopentyl-2-phenylacetamide,

16 - (2R) (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
17 cyclopentyl-2-phenylacetamide,

18 - (2S) (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
19 cyclopentyl-2-phenylacetamide

20 and their pharmaceutically acceptable salts.

1 23. The method according to claim 11 wherein said testosterone 5 α -eductase inhibitor
2 is a type 1 or a type 2 or both a type 1 and type 2 or a dual type 1 and type 2 inhibitor.

1 24. The method according to claim 23 wherein the testosterone 5 α -reductase inhibitor
2 is a dual type 1 and type 2 inhibitor.

1 25. The method according to claim 24 wherein the dual type 1 and type 2 inhibitor is
2 dutasteride.

1 26. The method according to claim 23 wherein the testosterone 5 α -reductase inhibitor
2 is a type 2 inhibitor.

1 27. The method according to claim 26 wherein the type 2 inhibitor is finasteride.

1 28. A pharmaceutical product or medicament comprising a first pharmaceutical
2 composition of a component selected from

3 - 5,6-dihydroxy-2-{3-[4-(2-isopropoxyphenyl)-piperazin-1-yl]propyl}-hexahydro-
4 isoindole-1,3-dione,

5 - 1-{3-[4-(2-isopropoxyphenyl)piperazin-1-yl]propyl}-piperidine-2,6-dione,

6 - 2-{3-[4-(2-ethoxyphenyl)piperazin-1-yl]propyl}-3a,4,7,7a-tetrahydro-isoindole-1,3-
7 dione,

8 - 1-(3-{4-[2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl}propyl)piperidine-2,6-dione,

9 - 5-hydroxy-2-(3-{4-[2-(2,2,2-trifluoroethoxy)phenyl]-piperazin-1-yl}propyl)-
10 hexahydro-isoindole-1,3-dione,

11 - 2-{3-[4-(2-Ethoxyphenyl)piperazin-1-yl]propyl}-5-hydroxy-hexahydro-isoindole-
12 1,3-dione,

13 - 2-{3-[4-(2-Ethoxyphenyl)piperazin-1-yl]propyl}-5,6-dihydroxy-isoindole-1,3-dione,

14 - 4,7-dihydroxy-2-{3-[4-(2-isopropoxyphenyl)-piperazin-1-yl]propyl}-hexahydro-
15 isoindole-1,3-dione,

- 16 - 3-Allyl-1-{3-[4-(2-methoxyphenyl)-piperazin-1-yl]propyl}-4-methyl-pyrrolidine-2,5-
17 dione,
18 - 1-(2-Hydroxy-3-{4-[2-(2,2,3,3,3-pentafluoropropoxy)phenyl]-piperazin-1-
19 yl}propyl)-piperidine-2,6-dione
20 or their pharmaceutically acceptable salts,
21 a second pharmaceutical composition of a muscarinic receptor antagonist,
22 an optional third pharmaceutical composition of testosterone 5 α -reductase inhibitor.